ABSTRACT AIMS -To investigate the lifetime prevalence and moderators of non-medical AAS use in the five Nordic countries. METHODS -We conducted a meta-analysis and meta-regression using studies gathered from searches in PsycINFO, PubMed, ISI Web of Science, Google Scholar, and reference checks. Included were 32 studies that provided original data on 48 lifetime prevalence rates based on a total of 233,475 inhabitants of the Nordic countries. RESULTS -The overall lifetime prevalence obtained was 2.1% [95% confidence interval (CI): 1.3-3.4, I 2 = 99.5, P < 0.001]. The prevalence for males, 2.9% (95% CI: 1.7-4.8, I 2 = 99.2, P < 0.001), was significantly higher (Q bet = 40.5, P < 0.001) than the rate for females, 0.2% (95% CI: 0.1-0.4, I 2 = 90.5, P < 0.001). Sweden has the highest prevalence of AAS use: 4.4%, followed by Norway: 2.4%, Finland: 0.8%, Iceland: 0.7%, and Denmark: 0.5%. Country, sample type, and male sample percentage significantly predicted AAS use prevalence in a meta-regression analysis. No indication of publication bias was found. CONCLUSION -Though subject to some limitations, our findings suggest that non-medical AAS use should be regarded as a serious public health problem in the Nordic countries.
Introduction
Anabolic-androgenic steroids (AAS) are a group of hormones including testosterone and its synthetic derivatives. These hormones are used clinically to treat conditions such as reproductive system dysfunction, breast cancer, and anemia. Increasingly, some healthy individuals have been using AAS for non-medical purposes (Boyadjiev, Georgieva, Massaldjieva, & Gueorguiev, 2000; Sagoe, Molde, Andreassen, Torsheim, & Pallesen, 2014a) . Nonmedical AAS use was mainly restricted to elite athletes and bodybuilders in the 1960s and 1970s as a means to enhance strength and athletic performance (Yesalis & Bahrke, 1995) . Non-medical AAS use has however spread into the general population in the last few decades (Kana yama, Hudson, & Pope, 2008 ) mainly driven by a desire for boosting physical strength and improving appearance (Kanayama, Hudson, & Pope, 2010; Parkinson & Evans, 2006; Tanner, Miller, & Alongi, 1995) . Indeed, results from a recent global epidemiological investigation indicates that recreational sportspeople constitute the largest group of AAS users (Sagoe et al., 2014a) .
There is extensive evidence connecting long-term AAS use to criminality (Lood, Eklund, Garle, & Ahlner, 2012; Lundholm, Haggård, Möller, Hallqvist, & Thiblin, 2013) and several debilitating physical and psychological disorders as well as mortality (Bahrke & Yesalis, 2004; Dodge & Hoagland, 2011; Hoffman & Ratamess, 2006; Kanayama et al., 2008; Pallesen, Jøsendal, Johnesen, Larsen, & Molde, 2006; Urhausen et al., 2004) . Despite such evidence of the harmful consequences of non-medical use, AAS seem to be among the least studied of the world's major abused drugs (Pope et al., 2013) . Hence, Degenhardt and Hall (2012) did not investigate the prevalence of AAS use in their study of the global prevalence of illicit drug use and dependence because of the scarcity of information regarding the AAS use epidemiology compared to drugs such as cocaine and cannabis. Kanayama, Hudson, and Pope (2012) suggest that the prevalence of AAS use is higher in the Nordic countries compared to most other parts of the world. Several epidemiological investigations of AAS use have been conducted in the Nordic countries. However, to our knowledge, there has never been a pan-Nordic meta-analytic investigation of the prevalence of AAS use. Thus, we conducted a meta-analysis on the lifetime prevalence of non-medical AAS use in the Nordic countries. We calculated overall prevalence estimates across the Nordic countries, gender, publication year, sample type, and sampling method. We further investigated the predictive effect of the above study variables on the overall lifetime prevalence rate using a meta-regression analysis.
Methods

Literature search strategy and inclusion criteria
We conducted a systematic and comprehensive literature search in PsycINFO, PubMed, ISI Web of Science, and Google Scholar for articles published between 1970 and July 2013. The following keywords: 'anabol*', 'steroid*', 'doping' were each used in combination with 'preval*', 'epidem*', and 'incidence' for the search. hered to Calabria et al.'s (2009) (Hibell et al., 2000 (Hibell et al., , 2004 (Hibell et al., , 2007 (Hibell et al., , 2009 (Hibell et al., , 2012 (Stroup et al., 2000) . Figure 1 presents the literature search and selection process.
Description of studies
Five articles (Hibell et al., 2000 (Hibell et al., , 2004 (Hibell et al., , 2009 (Hibell et al., , 2012 Nilsson, Baigi, Marklund, & Fridlund, 2001a (Haug & Ingvaldsen, 1974; Solberg, 1974) to 2013 (Nøkleby, 2013; Singhammer, 2013; Lindqvist et al., 2013) . Most studies were conducted in Sweden (n = 20), followed by Norway (n = 13), Finland (n = 7), Iceland (n = 5), and Denmark (n = 3). The study characteristics are presented in Table 1 .
Data extraction
Studies were scrutinized and selected based on their titles, abstracts, and subject matter by the first author. We developed a standardized data extraction form. Using this form, the first author and another reviewer independently extracted data from the identified studies. The following data were extracted from the included studies:
author name and publication year, country, and region of research, type of sample (prisoners and arrestees, recreational sportspeople, drug users, athletes, nonathletes, and high school), assessment method (questionnaires or interview), sampling method (random or non-random), sample size (total, male, and female), age of participants (range, mean, and standard deviation), response rate, and lifetime prevalence rate of AAS use reported (male, female, and overall). The inter-reviewer reliability for the reviewers for 162 studies identified in the first part of the search was found to be Kappa = 0.854 (P < 0.001) indicating an almost perfect agreement between the two reviewers (Viera & Garrett, 2005) . Consensus was reached on discrepant extractions between the two reviewers through further review and discussion of the articles. A final table of all studies is presented in Table 1 .
Publication bias
We assessed publication bias visually by funnel plot and statistically by the trim and fill procedure (Duval & Tweedie, 2000) in 
Statistical analysis
We conducted a meta-analysis and metaregression analysis to estimate the lifetime prevalence, as well as predictors of lifetime AAS use prevalence, in the Nordic countries. The meta-analysis and meta-regression analysis were conducted using Comprehensive Meta-Analysis, version 3.0 (Biostat Inc., 2014) . In calculating overall prevalence figures, relevant study characteristics (see Table 1 ) were coded for each study in Comprehensive MetaAnalysis, version 3.0. Thus, we were able to calculate pooled prevalence figures for relevant study characteristics based on the coded data for each study.
The calculation of prevalence rates and 95% CI was done using a random-effects model because it is most useful when the studies included in the meta-analysis 1970-1989, 1990-1999, and 2000-2013) , and the percentage of With reference to sample type, drug users had the highest overall prevalence rate: 59.2%, followed by athletes: 32.3%, prisoners and arrestees: 26.2%, and recreational sportspeople 2.1%. Moreover, prevalence rate for non-athletes was 1.2% while high school students had the lowest prevalence rate: 0.9%. With the exception of recreational sportspeople, the heterogeneity statistic (Q) for the overall prevalence rates for all sample types reached statistical significance (P < 0.001).
Results
Prevalence rates and heterogeneity testing
In addition, studies that used nonrandom sampling methods had a higher overall prevalence rate, 18.7%, than studies that used random sampling methods, 1.0%. 
Meta-regression analysis
We performed a meta-regression analysis to evaluate the effect of country, sample type, sampling method, publication year, Table 3 .
Discussion
This paper presents, to our knowledge, the first-ever meta-analysis and meta-regression analysis of the lifetime prevalence of AAS use specifically for the Nordic countries. The lifetime prevalence rate across all studies was 2.1%. Moreover, the overall lifetime prevalence rate for males, 2.3%, was significantly higher than the overall lifetime prevalence rate for females, 0.2% confirming the preponderance of available evidence (Andrade et al., 2012; Johnson, Jay, Shoup, & Rickert, 1989; Kindlundh, Isacson, Berglund, & Nyberg, 1998; Sagoe et al., 2014a) .
We found further support for this result in the finding that percentage of males in samples significantly predicted prevalence in the meta-regression analysis consistent with results from a worldwide prevalence study (Sagoe et al., 2014a) . In addition, we found that Sweden has the highest prevalence rate of AAS use: 4.4%, The finding that studies using non-random sampling methods report a higher prevalence rate than studies based on random sampling methods seems to be related to the fact that the predominance of nonrandomly selected samples comprised athletes, prisoners, arrestees, and drug users among whom AAS use prevalence is relatively higher compared to high school students and non-athletes, as previously found (Baker, Thomas, Davies, & Graham, 2008; Bojsen-Møller & Christiansen, 2010; Grace, Baker, & Davies, 2001; Lood et al., 2012) . However, sampling method was in- 
